Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 12/20 | 1.00 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | AKT1 | P31749 | 2/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30184535 | 1.00 | NOTUM (1.00) | NOTUMDRD4KDM4EALDH1A1MAPT | |
| SCHEMBL24011117 | 0.90 | NOTUM (0.82) | NOTUMDRD4KDM4EALDH1A1MAPT | |
| SCHEMBL30659423 | 0.85 | NOTUM (0.73) | NOTUMDRD4KDM4EALDH1A1HPGD | |
| SCHEMBL23042904 | 0.85 | NOTUM (0.73) | NOTUMDRD4KDM4EALDH1A1HPGD | |
| SCHEMBL16600344 | 0.83 | NOTUM (0.71) | NOTUMDRD4AKT1 | |
| SCHEMBL26667117 | 0.83 | NOTUM (0.71) | NOTUMDRD4AKT1 | |
| SCHEMBL5568369 | 0.83 | NOTUM (0.70) | NOTUMDRD4KDM4EAKT1 | |
| SCHEMBL6687673 | 0.81 | NOTUM (0.71) | NOTUMCYP2D6CYP2C9POLB | |
| SCHEMBL4532424 | 0.81 | NOTUM (0.71) | NOTUMCYP2D6CYP2C9POLB | |
| SCHEMBL2619231 | 0.81 | NOTUM (1.00) | NOTUMDRD4ALDH1A1MAPTCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112321478-A | Synthetic method of 4-fluoro-7-nitroindole or derivative thereof | 上海代为化学科技有限公司 | 2021-02-05 | — | — | CN | claimed |
| US-20240400591-A1 | COMPOUNDS TARGETING MUTANT OF P53 | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-12-05 | — | — | US | disclosed |
| CN-117813295-A | Compounds targeting p53 mutants | 北京加科思新药研发有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-117534665-A | Diacylglycerol kinase inhibitors | 山东轩竹医药科技有限公司 | 2024-02-09 | — | — | CN | disclosed |
| WO-2023016434-A1 | COMPOUNDS TARGETING MUTANT OF P53 | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2023-02-16 | — | — | WO | disclosed |
| CN-112321478-A | Synthetic method of 4-fluoro-7-nitroindole or derivative thereof | 上海代为化学科技有限公司 | 2021-02-05 | — | — | CN | disclosed |
| WO-2017153952-A1 | 5-SULFAMOYL-2-HYDROXYBENZAMIDE DERIVATIVES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-09-14 | — | — | WO | disclosed |
| US-9452168-B2 | Pyrrole antifungal agents | F2G LTD (GB) | 2016-09-27 | — | — | US | disclosed |
| EP-2029543-B1 | SUBSTITUTED 3-CYANOPYRIDINES AS PROTEIN KINASE INHIBITORS | WYETH LLC (US) | 2015-11-18 | — | — | EP | disclosed |
| US-20150238500-A1 | PYRROLE ANTIFUNGAL AGENTS | F2G LTD (GB) | 2015-08-27 | — | — | US | disclosed |
| EP-2283006-B1 | PYRROLE ANTIFUNGAL AGENTS | F2G LTD (GB) | 2015-02-25 | — | — | EP | disclosed |
| EP-2626361-B1 | Pyrrole antifungal agents | F2G LTD (GB) | 2014-10-15 | — | — | EP | disclosed |
| EP-2626361-A1 | Pyrrole antifungal agents | F2G Limited (GB) | 2013-08-14 | — | — | EP | disclosed |
| US-20110152285-A1 | PYRROLE ANTIFUNGAL AGENTS | F2G LTD (GB) | 2011-06-23 | — | — | US | disclosed |
| EP-2283006-A1 | PYRROLE ANTIFUNGAL AGENTS | F2G Limited (GB) | 2011-02-16 | — | — | EP | disclosed |
| US-7781591-B2 | Substituted 3-cyanopyridines as protein kinase inhibitors | WYETH LLC (US) | 2010-08-24 | — | — | US | disclosed |
| WO-2009130481-A1 | PYRROLE ANTIFUNGAL AGENTS | F2G LTD (GB) | 2009-10-29 | — | — | WO | disclosed |
| US-20070287708-A1 | Substituted 3-cyanopyridines as protein kinase inhibitors | WYETH LLC | 2007-12-13 | — | — | US | disclosed |
| EP-1701954-A1 | N-SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES | Warner-Lambert Company LLC (US) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005066165-A1 | N-SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400591-A1 | COMPOUNDS TARGETING MUTANT OF P53 | TP53, TP53BP1, MDM2 | NOTUM 4541/4885DRD4 4693/4885KDM4E 4363/4885 |
| US-20070287708-A1 | Substituted 3-cyanopyridines as protein kinase inhibitors | CNKSR1, MAP3K1, MAP3K7 | NOTUM 3646/4885DRD4 4798/4885KDM4E 859/4885 |
| US-20110152285-A1 | PYRROLE ANTIFUNGAL AGENTS | FOXM1, PYCR1, ARG1 | NOTUM 616/4885DRD4 1570/4885KDM4E 1706/4885 |
| US-20150238500-A1 | PYRROLE ANTIFUNGAL AGENTS | FOXM1, PYCR1, ARG1 | NOTUM 616/4885DRD4 1570/4885KDM4E 1706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.